Flt3 inhibitors for the treatment of acute myeloid leukemia

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 6, 2010, Pages 429-437

  Wiernik, Peter H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Acute lymphoblastic lymphoma; Acute myeloid leukemia; Flt3 inhibitors; Mtor inhibitors; Myelodysplastic syndromes; Natural killer cells

Indexed keywords

AC 220; AFINITOR; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; EVEROLIMUS; IDARUBICIN; KW 2449; LESTAURTINIB; MIDOSTAURIN; MITOXANTRONE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TANDUTINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOKALEMIA; LIMB PAIN; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NONHUMAN; PANCYTOPENIA; PLASMA CONCENTRATION-TIME CURVE; PLEURA EFFUSION; PNEUMONIA; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION;

EID: 77954494236     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Illmer T, Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin Lymphoma Myeloma. 2007;8(suppl 1):S24-S34.
2. Amadori S. New agents for the treatment of acute myeloid leukemia. Hematol Meeting Rep. 2008;2:159-161.
3. Mead AJ, Gale RE, Kottaridis PD, et al. Acute myeloid leukemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with FLT3 internal tandem duplication. Br J Haematol. 2008;141:454-460.
4. Santos FP, Qiao W, Cortes JE, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML). J Clin Oncol. 2009; 27: 15s. Abstract 7015.
5. Burnett AK. Lestaurtinib as a FLT3 inhibitor. Hematol Meeting Rep. 2008; 162-163.
6. Mori Y, Kiyoi H, Ishikawa Y, Naoe T. FL-dependent wild-type FLT3 signals reduce the inhibitory effects of FLT3 inhibitors on wild-type and mutant FLT3 co-expressing cells. Blood. 2009; 114: 816. Abstract 2067.
7. Von Bubnoff N, Engh RA, Aberg E, et al. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009;69:3032-3041.
8. Pratz KW, Sato T, Murphy KM, et al. FLT3 mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115:1425-1432.
9. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295: 2097-2100.
10. Salih J, Kanz L, Salih HR, Krusch M. The FLT3-inhibitors midostaurin, sunitinib, sorafenib, and TK1258 differentially affect NK cell-mediated immu-nosurveillance of acute myeloid leukemia. Blood. 2009;114:1455. Abstract 3785.
11. Nishioka C, Ikezoe T, Yang J, et al. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res. 2008;32:865-872.
12. Weisberg E, Barrett R, Liu Q, et al. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009;12:81-89.
13. Levis M, Sato T, Murphy K, et al. FLT3 mutant to wild type allelic ratio and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2009;114:684. Abstract 1716.
14. Alvares CL, Schenk T, Hulkki S, et al. Non-cycling cells from acute myeloid leukemia patients harbor the FLT3-ITD mutation and are insensitive to TK1258, a potent FLT3 directed inhibitor, in vitro. Blood. 2009;114:197. Abstract 479.
15. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215-6224.
16. Breitenbuecher F, Markova B, Kasper S, et al. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood. 2009;113:4063-4073.
17. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009;114:5034-5043.
18. Kojima K, Konopleva M, Tsao T, et al. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia. 2010;24:33-43.
19. Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005;280:35217-35227.
20. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007;67:9490-9500.
21. Al-Kali A, Jones D, Cortes J, et al. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with newly diagnosed FLT3-mutant acute myeloid leukemia. Blood. 2009;114: 820. Abstract 2079.
22. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008;22:808-818.
23. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100:184-198.
24. Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 2007;21:439-445.
25. Mori S, Cortes J, Kantarjian H, et al. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008;49:2246-2255.
26. Pratz KW, Cho E, Karp J, et al. Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol. 2009; 27:15s. Abstract 7065.
27. Metzelder S, Scholl S, Matthias K, et al. Compassionate use of sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia. Blood. 2009;114: 813. Abstract 2060.
28. Schroeder T, Saure C, Bruns I, et al. Clinical efficacy of sorafenib in patients with acute myeloid leukemia (AML) and activating FLT3-mutations. Blood. 2009;114: 812. Abstract 2057.
29. Safaian NN, Czibere A, Bruns I, et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res. 2009;33:348-350.
30. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113:6567-6571.
31. Lee SH, Paietta E, Racevskis J, Wiernik PH. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol. 2009;84:701-702.
32. Ravandi Kashani F, Cortes J, Faderl S, et al. Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML). J Clin Oncol. 2009; 27: 15s. Abstract 7018.
33. Yee KW, Schittenhelm M, O'Farrell AM, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemia cells. Blood. 2004;104:4202-4209.
34. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003;9:5465-5476.
35. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105:986-993.
36. Nishioka C, Ikezoe T, Yang J, Yokoyama A. Sorafenib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D (3). Leukemia. 2009;23:2171-2173.
37. Hu S, Niu H, Minkin P, et al. Comparison of antitumor effects of multitar-geted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther. 2008;7:1110-1120.
38. Kancha RK, Grundler R, Peschel C, Duyster J. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol. 2007;35:1522-1526.
39. Ikezoe T, Nishioka C, Tasaka T, et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther. 2006;5:2522-2530.
40. Huang YC, Chao DK, Clifford Chao KS, Chen YJ. Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells. Toxicol in Vitro. 2009;23: 979-985.
41. Stone RM, Fischer T, Paquette R, et al. Phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT 3 mutations is similar to those with wild-type FLT3. Blood. 2009;114: 263. Abstract 634.
42. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008; 111:5663-5671.
43. Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004; 104:1145-1150.
44. Brown P, Levis M, Mclntyre E, et al. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia. 2006;20:1368-1376.
45. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3262-3270.
46. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse. Blood. 2009;114: 325. Abstract 788.
47. Sato T, Knapper S, Burnett AK, et al. Increased plasma FLT3 ligand levels following chemotherapy may interfere with the clinical efficacy of FLT3 inhibitors. Blood. 2009; 114: 387. Abstract 937.
48. DeAngelo DJ, Stone RM, Heaney ML, et al. Phase I results with tanduti-nib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006;108:3674-3681.
49. Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC. The FLT3 inhibitor Tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle. 2009;8:2621-2630.
50. Cheng Y, Paz K. Tandutinib, an oral, small-molecular inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs. 2008;11:46-56.
51. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114:2984-2992.
52. Chao Q, Sprankle KG, Grotzfeld RM, et al. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo{2,1-b] [1,3] benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem. 2009;52:7808-7816.
53. James J, Pratz K, Stone A, et al. Clinical pharmacokinetics and FLT3 phosphorylation of AC220, a highly potent and selective inhibitor of FLT3. Blood. 2008;112. Abstract 2637.
54. Brigham D, Belli BA, Breider M, et al. AC220, a FLT3 inhibitor, increases survival in two genotypically distinct FLT3-ITD models of acute myeloid leukemia and provides sustained protection following chronic administration. Blood. 2009;114: 810. Abstract 2053.
55. Belli BA, Dao A, Bhagwat S, et al. AC220, a potent and specific FLT3 inhibitor, enhances the cytotoxic effects of chemotherapeutic agents in cell culture and in mouse tumor xenografts. Blood. 2009;114:810. Abstract 2052.
56. Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multi-kinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009;114:1607-1617.
57. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther. 2007;6:1851-1857.
58. Pratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009;113:3938-3946.
59. Pratz KW, Stine A, Karp J, et al. Optimizing the dose and schedule of KW-2449, FLT3/Aurora inhibitor, through analysis of in vivo target inhibition. J Clin Oncol. 2008; 26:15s. Abstract 7069.
60. Cortes J, Roboz GJ, Kantarjian HM, et al. A phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML. Blood. 2008;112. Abstract 2967.
61. Pemmaraju N, Kantarjian HM, Ravandi F, et al. Flt3 inhibitor therapy for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): impact on survival according to FLT3 status. Blood. 2009; 114: 424. Abstract 1026.
62. Jin G, Matsushita H, Asai S, et al. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun. 2009;390:1001-1006.